Translational efficacy biomarkers
Drug discovery projects are massively speeded up if a biochemical efficacy biomarker is available: Target response can be followed from cell culture over animal to man.
The method of choice for metabolic markers is LC/MS – often hardly available and disregarded at discovery level, but readily available from 3rd party labs. I have extensive experience with many markers (see list). Let me help to bridge this gap.
DMPK and ADME analytics
LC/MS has become the most important analytical method in DMPK assessment due to its capabilities in both quantitative and qualitative analysis. The choice of the suitable MS technology is pivotal for meaningful results.
Our experience with both kinetic, enzymological and metabolic studies for drug discovery qualifies us for research partnerships in your projects.
Mass spectrometric assay readouts
Mass spectrometry allows sensitive multiplex detection of metabolic assay readouts at limited throughput. Ideally suited for mechanistic studies and/or selectivity assays and counterscreens.
Once a method is established it will also serve as translational target response biomarker.
Mass Spectrometry expertise
Mass spectrometry and LC/MS play a pivotal role in drug discovery, e.g. in drug metabolism, compound purity and stability assessment, in the deconvolution of mode of action in phenotypic drug discovery projects or in the above mentioned biomarker area. My expertise covers most pharma applications and I can support you with advice, courses, coaching and outsourcing.
Read on the analytics page what LCMS can contribute in drug discovery.
Technology advice in drug discovery
A plethora of technologies and methods are evolving to support drug discovery. All of them have advantages and drawbacks and not always both are clearly stated. Sometimes, in spite of overwhelming amounts of biochemical detail information, important pharmaceutical questions remain open. In the interest of minimal drug development times and costs it is more important than ever to stay focused on the ultimate goal of pharma research, the patient’s recovery.
Preclinical - clinical project management
Together with our safety and clinical partner PKI we manage preclinical projects for startup companies. In this connection PKI takes care for the later stages and regulatory aspects and smv3 contributes discovery and analytical competence.
We can assess your project portfolio and come up with a gap analysis. If desired we then plan and manage the completion of missing data.
Your project has a specific issue? You heard about an attractive new technology? Contact me for a first discussion and subsequent steps will be made after a CDA is established.
Web and Design
Illustrations for Life Sciences
Biotech and pharma startups need webmasters and graphic designers who are not only multilingual but also speak the ‘life science language’ and understand the complex relationships in biology, technology and life. My experience in drug discovery, my graphical talent and my language and informatics skills make me a suitable creator for your publication.
Read on the graphics page what matters in scientific communication.